I'm LongbridgeAI, I can summarize articles.Goldman Sachs analyst Salveen Richter maintained a Sell rating on Intellia Therapeutics with a $9 price target. The decision reflects clinical and commercial uncertainties, including a delayed approval timeline for lonvo-z until H1 2027, competitive positioning challenges in the HAE market, and execution risks in the broader CRISPR pipeline.
Goldman Sachs analyst Salveen Richter maintained a Sell rating on Intellia Therapeutics yesterday and set a price target of $9.00.
Claim 55% Off TipRanks
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Salveen Richter has given his Sell rating due to a combination of factors related to both clinical and commercial considerations. While the latest Phase 3 data for lonvo-z in hereditary angioedema show robust reductions in attack rates and meaningful quality-of-life improvements, the approval timeline extends out to an anticipated decision in the first half of 2027, limiting near- to medium-term revenue contribution.
Richter also highlights uncertainty around how lonvo-z will be positioned in an already competitive HAE market, where some physicians and patients may favor established chronic therapies with well-characterized long-term safety over an irreversible gene-editing approach. In addition, the company’s broader CRISPR pipeline, including the nex-z program in transthyretin amyloidosis, faces timeline and execution risks, particularly around large, ongoing Phase 3 studies, which contributes to a more cautious stance and supports maintaining the unchanged $9 price target alongside the Sell rating.